Axsome Therapeutics, Inc — Quarterly Financial Statements (NASDAQ:AXSM) | MetaTrader

Open full chart

Financials

Overview Estratto Conto Statistics Dividends

Quarterly Annual

Market Capitalization 8.1531 B
Employee 816
Founded 2012
CEO Herriot Tabuteau
Website www.axsome.com
Headquarter Delaware, United States
FIGI BBG00B6G7GL7
Industry Technology

Total revenue

Net income

Basic earnings per share (Basic EPS)

Total debt

Free cash flow

Cash & equivalents

8.15 B Market capitalization

Price to earnings ratio

-49.63

Price to sales ratio

14.23

Dividends per share

—

Dividend yield %

—

Notizie

Stock Market Can't Hold Key Levels Amid AI Concerns; Nvidia Tumbles Despite Strong Earnings: Weekly Review

Construction Star Leads 11 Hot Stocks To Various Best Growth Lists like IBD 50, Sector Leaders

AXSM Q4 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales

UBS alza il target su Axsome Therapeutics per l’espansione della forza vendita

UBS raises Axsome Therapeutics stock price target on sales force expansion

Wolfe Research avvia la copertura su Axsome con rating outperform

Wolfe Research initiates Axsome stock with outperform rating

RBC Capital alza il target su Axsome Therapeutics dopo i risultati

RBC Capital raises Axsome Therapeutics price target on earnings

Axsome somministra il primo paziente nello studio sulla depressione con solriamfetol

Axsome doses first patient in depression trial with solriamfetol

Guggenheim alza il target di Axsome a 220$ su vendite solide